Author: OneMedPlace Team
Omeros Corporation (OMER) will soon begin two mid stage clinical trials on its drug OMS824 which has greatly increased its stock prices. The company is testing its drug as a treatment for Huntington’s disease toward the end of 2013 as well as trials involved the treatment of Schizophrenia. The FDA has also awarded OMS824 orphan drug status as a treatment for Huntington’s. These two neurological disorders have been diagnosed in numerous Americas. The positive outlook thus far on this drug looks promising.
View the full article here (http://finance.yahoo.com/news/omeros-prepares-two-studies-oms824-182145630.html).